Policy stances from the incoming Trump administration, bullish quarterly earnings and an “Elon Musk premium” led to lofty stock returns, experts said.
Related Posts
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.
UN says Israeli strike killed six of its Gaza staff
At least 18 people were reportedly killed in the strike, which Israel says targeted Hamas fighters.
CNBC’s The China Connection newsletter: A tech boom is underway
China’s tech world isn’t getting distracted by whether the U.S. and China will talk on trade.